AcouSort

revolutionizing sample processing

Participation in SLAS, Phacilitate, and KIMES conferences to engage with new potential customers across the cell therapy, lab automation, and diagnostics segments.

AcouSort's separation technology exhibited at Analytica in collaboration with Moeller Medical.

Two new AcouWash systems placed with industrial and academic partners.

Q1

INTERIM REPORT
JANUARY 1 – MARCH 31, 2026
ACOUSORT AB (PUBL)

Summary of the interim report

SIGNIFICANT EVENTS DURING THE FIRST QUARTER

- On January 23, AcouSort announced it has initiated a feasibility project with a large international manufacturing company aiming at investigating the applicability of AcouSort's technology for removing particles in different steps of production workflows.
- On March 10, AcouSort announced the signing of an amendment to its license and distribution agreement with the leading blood-gas analyzer company, Werfen. Under the amendment, Werfen will prepay minimum royalties for 2027 and 2028. Together with Werfen's regular 2026 minimum royalty, the total sum payable to AcouSort in early 2026 amounts to approximately USD 1.3 million.
- On March 16, AcouSort announced its German partner Moeller Medical, a developer and manufacturer of high-precision medical solutions, will exhibit a prototype system for analyzing body fluids at the Analytica trade fair in Munich, March 24-27. The system includes AcouSort's novel AcouWash technology.

SIGNIFICANT EVENTS AFTER THE END OF THE PERIOD

- On April 16, AcouSort announced the sale of an AcouTrap system to a research group led by Alisa Komsky-Elbaz, PhD, Assistant Professor at the Hebrew University of Jerusalem.

FINANCIAL SUMMARY

The "Company" or "AcouSort" refers to AcouSort AB (publ) with corporate registration number 556824–1037.

First quarter 2026 for the Group

- Net sales amounted to TSEK 2,147 (1,595)
- Result before tax amounted to TSEK –2,369 (-4,022)
- Result per share* was SEK -0.10 (-0.27)
- Equity ratio** amounted to 52% (41%) on March 31, 2026

First quarter 2026 for the Parent company

- Net sales amounted to TSEK 2,144 (1,569)
- Result before tax amounted to TSEK -2,301 (-3,915)
- Result per share* was SEK -0.11 (-0.26)
- Equity ratio** amounted to 55% (54%) on March 31, 2026

* Earnings/loss per share: Profit/loss for the period divided by 21,163,902 shares. In the year-earlier period, the company had 14,923,858 shares.
** Equity ratio: Equity divided by total capital.

NOTE TO THE READER

Amounts in parentheses refer to corresponding period of the previous year.

This document is essentially a translation of the Swedish language version. In the event of any discrepancies between this translation and the original Swedish document, the latter shall be deemed correct.

Our positive trend continued in Q1 2026

We have started this year with the same positive and inspirational momentum that characterized 2025. We continue to strengthen our presence in the lab-automation and cell therapy space, with more fruitful interactions and collaborations that will ultimately strengthen AcouSort. Total income in the quarter amounted to MSEK 2.3 (2.6), of which net revenues amounted to MSEK 2.2 (1.6). Royalty income amounted to MSEK 1.4 (1.3)

A GROWING NETWORK OF COLLABORATIONS

Our core strategy is to achieve commercial success by establishing close collaborations with other companies, with the aim to ultimately establishing long-term OEM partnerships.

Already in January, we announced the start of a new feasibility project with a large international manufacturing company aiming at investigating the applicability of our technology for removing particles in different steps of production workflows. This is a very exciting project that demonstrates the versatility of AcouSort's technology, and we are very excited over the opportunity this new collaboration brings.

After the period, in April, we sold an AcouTrap system to a research group led by Dr. Alisa Komsky-Elbaz, PhD, Assistant Professor at the Hebrew University of Jerusalem. The AcouTrap system is especially suitable for the group's work as they often work with minute samples that are difficult to handle using other technologies, and where the AcouTrap has shown to be particularly well suited to manage their samples.

Dr. Komsky-Elbaz's research group works within the field of reproductive medicine and studies extracellular vesicles (EVs) and their role in cell-to-cell communication, with emphasis on biological processes related to reproduction and early development. Revenues generated from the sales of the AcouTrap system is expected to be €38,000.

INTENSIVE PERIOD FOR BUSINESS DEVELOPMENT

The first contacts with potential partners are typically made at international conferences and trade fairs, and even though we are a small team, we make it a point to be present at different significant international events where we have the possibility to meet new potential partners, as well as continue developing our relationships with existing ones.

Our strategic partnerships allow us to showcase the seamless integration of our technology within next-generation systems. An excellent example of how we collaborate with our partners was when Moeller Medical, a developer and manufacturer of high-precision medical solutions, in March exhibited a prototype system for analyzing body fluids at the Analytica trade fair in Munich, Germany. The system includes AcouSort's novel AcouWash technology. This gave us a great opportunity to show integration of our acoustic separation technology into new point-of-care diagnostic instrumentation.

Our collaboration with Moeller Medical was originally initiated in 2024 and extended last year when the German company ordered additional separation modules for clean-up of fluid samples for integration into their research prototypes.

We plan to continue attending important conferences in 2026 where we can meet companies that are working on current and next generation cell therapies where AcouSort has the potential to play a vital role. The significantly increased influx of new potential OEM projects proves that our intensified marketing efforts at conferences and trade fairs after the Covid pandemic is paying off.

PREPAYMENT OF ROYALTIES PUTS US ON SOLID FINANCIAL GROUND INTO 2027

In March, we signed an amendment to our license and distribution agreement with the leading blood-gas analyzer company, Werfen. Under the amendment, Werfen will prepay minimum royalties for 2027 and 2028. Together with Werfen's regular 2026 minimum royalty, the total sum payable to AcouSort in early 2026 amounted to approximately USD 1.3 million and based on our current cash position and this prepayment, together with Werfen's regular 2026 minimum royalties, the company will be fully funded into 2027. This is of course a boost for our ongoing and future business and provides additional basis for securing long-term financing.

OUTLOOK

Our ambition now is to continue strengthening our positions in diagnostics, cell therapy and lab automation by continuing to develop existing and future partnerships over the coming year. With a stable financial position and a very proficient organization, as well as a growing collaboration network, we will now be able to take AcouSort to the next exciting stage and shape the future of the company. I will keep you updated as we make progress in our projects.

Torsten Freltoft – CEO
ACOUSORT AB

AcouSort at a glance

AcouSort is an innovative medical technology company developing critical components for instrumentation used in the diagnostics, cell therapy production and lab automation markets. AcouSort's components allow for automated refinement of biological samples such as blood or cell preparations, providing instrumentation manufacturers with a state-of-the-art ability to integrate sample processing steps that traditionally have to be performed manually.

OUR VISION & MISSION

Our vision is to improve healthcare impact and save lives across the globe by enabling more and better healthcare, faster! Our mission is to lead and drive the development and implementation of a new gold standard for automated sample preparation in clinical research, diagnostics and therapeutics. By providing solutions that radically change the way healthcare is provided today, we remove the bottlenecks for tomorrow's standard of care.

To realize our vision, AcouSort's main goals are:

- Support biomarker discovery and diagnostic assay development for critically ill patients with high sense of urgency
- Enable significant growth of the point-of-care market across healthcare sectors
- Streamline and automate cell processing to allow cell therapeutics to become broadly accessible
- Stay in the forefront of the acoustofluidics technology by continuously engaging in R&D activities with relevant international academics and life science players

By pursuing these goals, AcouSort aims to become the leading supplier of acoustofluidic sample preparation solutions for the healthcare market.

OUR STRATEGY & BUSINESS CONCEPT

AcouSort's strategy is to use our innovative technology to revolutionize today's healthcare by providing a solution to automate and integrate sample processing steps, allowing for a new generation of medical devices to be developed. Through collaborations with leading Life Science companies our integrated technology will eliminate manual handling steps while saving time, money, and ultimately – lives.

Our commercialization strategy builds on our validated OEM business model offering sample preparation modules and solutions to providers of lab automation instrumentation, diagnostic equipment, and therapeutic systems. Through close collaborations we develop customized implementations of our core technology tailored to our partner's needs. AcouSort holds an ISO13485 certificate for the design, development, and manufacturing of components for the Medical Device industry.

To simplify evaluation of the technology, we have integrated our OEM components into user-friendly benchtop systems serving as innovation platforms for our partners. The systems are also used for sample preparation within research and assay development.

OUR TECHNOLOGY

AcouSort's core technology is acoustofluidics – a combination of sound waves (acousto) and microfluidics. Microfluidics allow for precise control of liquids while acoustics give us the ability to move particles of different biophysical properties. By combining the two technologies, we have the unique ability to move target cell types from one liquid to another. This allows us to fractionate the different components in a blood sample, isolate extracellular vesicles or wash cells to remove contaminants, without having any physical contact with the sample. As the technology is gentle and rapid, it provides a competitive alternative to conventional processing techniques such as centrifugation or filtration. By using acoustofluidics, AcouSort can streamline sample processing for a wide range of applications – from biomarker discovery in basic research, to preparation of clinical blood samples prior to analysis, or sample purification in cell therapy manufacturing.

AcouSort's core technology builds on more than 25 years of acoustofluidics research and development headed by Thomas Laurell, professor at Lund University at the Department of Biomedical Engineering and co-founder and board member of AcouSort.

AcouSort major milestones

2020	2021	2022	2023	2024	2025
• Changed trading venue to Nasdaq First North Growth Market • Received ISO13485 certification	• AcouWash 2 launched • First OEM product AcouPlasmaOptical launched	• Increased commercial focus targeting the cell therapy market	• EUR 12.5M in EU funding for the AcouSome project • AcouTrap 3 launched • First regulatory approved system containing acustofluidic technology	• Launch of first clinical system based on AcouSort background technology	• Launch of Evaluation kit with high-throughput OEM separation chip for cell wash applications addressing cell therapy production and lab automation markets

STRATEGY

Growth through research and innovation collaborations



AcouSort's acoustofluidic technology is perfectly placed to play a critical role in the healthcare of tomorrow. Cardiovascular diseases, infections, and cancer remain the leading causes of death globally, driving an urgent need for development of new and effective diagnostic and scalable cell therapeutic solutions.

Today's sample processing and manufacturing workflows are facing significant challenges as they rely on multiple manual handling steps. Manual work increases the risk of human errors, contamination and variability leading to high production costs and limits patient access to potentially life-saving diagnostics and treatments. The industry is therefore in clear need of new, enabling technologies that support automation, integration, and standardization.

SIGNIFICANT POTENTIAL IN CELL THERAPY, DIAGNOSTICS AND LAB AUTOMATION

AcouSort's ambition is to address some of the key challenges in cell therapy manufacturing by introducing solutions that enable automated and integrated sample processing. Our technology can be applied at several critical process steps to lower manufacturing costs, improve robustness, and support scalable production of cell-based therapies.

Within diagnostics, our ability to automate and integrate sample preparation enables the development of a new generation of diagnostic devices. By allowing analysis to be performed closer to the patient, at the point of care, results can be delivered immediately, supporting faster clinical decision-making and improved patient outcomes.

As laboratory and production workflows becomes more complex, demand is growing for automated solutions focusing on monitoring, quality control, and analytics. A growing share of AcouSort's industrial collaborations targets lab automation workflows, extending the use of our acoustofluidic technology for sample preparations.

GROWTH THROUGH OUR RESEARCH-TO-OEM MODEL

AcouSort's strategy is centered on its research-to-OEM business model, with the objective of establishing recurring revenues through sales of OEM modules to leading life science companies. Through multiple academic and industry partnerships across cell therapy, diagnostics, and lab automation, we are building a strong foundation for joint development and commercial integration of our technology.

AcouSort is currently targeting the North American and European markets, as well as selected markets in Asia.

INNOVATION WITH STRONG COMMERCIAL POTENTIAL

AcouSort's benchtop systems play an important role in supporting application development, technical validation, and maturation towards OEM integration. The systems are used in collaborations both with selected academic key opinion leaders and industry partners, providing early access to AcouSort's technology. These collaborations support the advancement of our technology with a clear focus on commercialization. Over the years AcouSorts innovation activities has partly been funded by the European Innovation Council (EIC), the EU, and Vinnova.

Cell & Gene Therapies Approved – World



Source: ASGCT_Citeline Q4 2022 Report

Accumulated AcouSort OEM projects and system placements



DIAGNOSTICS

Advancement within point-of-care testing requires automation of sample preparation



To address some of the world's most prevalent and costly diseases – cardiovascular diseases, infectious diseases, and cancer – healthcare systems must deliver faster, more accessible, and more cost-efficient diagnostics. This need is amplified by ageing populations and increasing healthcare demands globally. One of the most effective ways to meet these challenges is to move diagnostic testing closer to the patient, enabling rapid clinical decision-making and earlier intervention. AcouSort's integrated and automated sample processing provides an optimal solution to achieve this.

Today, decentralized and point-of-care diagnostic testing at scale remains challenging as most blood-based assays require blood plasma separation prior to analysis. Consequently, a large fraction of blood samples is still transported to central laboratories. To migrate these assays to point-of-care settings, in-line access to blood plasma is required for developing user-friendly diagnostic devices. AcouSort's acoustic separation modules are designed to address this challenge by enabling automated, label-free, and closed sample preparation solutions suitable for point-of-care instruments.

MARKET

Diagnostic testing is undergoing a structural shift from centralized laboratories towards decentralized and point-of-care settings. This market trend is driven by the need for faster turnaround times, reduced laboratory burden and improved patient outcomes. As testing moves closer to the patient, the adoption of more advanced diagnostics outside traditional laboratory environments is increasing, which in turn is driving demand for robust and automated sample preparation solutions.

The global point-of-care testing (POCT) market was valued at USD 44.7 billion in 2025 and is expected to grow to approximately USD 82 billion by 2034, corresponding to a compound annual growth rate (CAGR) of around 7%[1].

1 https://www.gminsights.com/industry-analysis/point-of-care-testing-market

OFFERING

AcouSort collaborates with developers of point-of-care diagnostic systems to customize and integrate our OEM acoustic separation modules into novel or next-generation systems. The OEM modules are designed for incorporation into consumable or semi-consumable cartridges developed by our partners for use in their diagnostic instruments.

As more system providers integrate our separation modules into their diagnostic systems, AcouSort's business model offers strong scalability and recurring revenue potential, driven by OEM module sales linked to cartridge and instrument sales volumes.

FOCUS 2026

In 2026, AcouSort will continue to expand its presence within the diagnostic segment by engaging with diagnostic system developers through conferences and trade fairs as well as with evaluation and demonstration activities. In parallel, AcouSort will continue to strengthen its marketing and technical communication, with a particular focus on highlighting the value of AcouPlasmaOptical supporting the transition of advanced assays from central laboratories to point-of-care diagnostic formats.

Activities 2026

Quarter 1

- Participation in Analytica conference where our collaboration partner Moeller Medical exhibited their new prototype system containing AcouSort technology to enable in-line cell removal before sample analysis.
- Business trip to Korea to meet with Korean diagnostic instrument developers and present AcouSort's AcouPlasma and Acoustic separation solutions.

CELL THERAPY

Automated cell processing facilitates the cell therapy revolution



The world is facing a revolutionary increase in clinically approved cell therapies during the coming years. Unfortunately, the complex and expensive manufacturing process significantly limits the access to these treatments. All major Life Science instrumentation companies have active programs targeting automation of the cell therapy processing to manage production cost and quality. AcouSort's automated cell separation and processing technology is well positioned to provide a new mainstream solution for these novel cell therapies.

The number of clinically approved cell and gene therapies continues to grow rapidly, with a substantial pipeline of new candidates in development. However, cell therapies are associated with high treatment costs of up to USD 500,000 per patient, limiting broad adoption and putting significant pressure on healthcare systems. These high costs are largely driven by complex manufacturing processes that rely on sterile facilities and extensive manual handling during cell processing, resulting in low scalability and high production risks.

MARKET

The global cell therapy market size was valued between USD 7-9 billion in 2025 and is expected to expand at a compound annual growth rate (CAGR) of 20-23% from 2025 to 2030[1] [2] [3], thus exceeding USD 47 billion in 2035. The market is constantly growing to include new cell therapies, which presents a significant opportunity for companies to strengthen their market positions. As a result, during the past few years, there has been a dramatic increase in the number of companies engaged in the development of cell therapies.

OFFERING

AcouSort has been approached by a handful of multinational Life Science companies seeking solutions to enclose and automate the cell therapeutics processing and eliminate the current manual processing. Our separation modules are well suited for this as they can automatically perform the cell wash, cell up-concentrations and separation of target cell types needed.

AcouSort's strategy is to develop and supply the automated cell processing modules as single use OEM components to our Life Science instrumentation partners. In this way, the AcouSort business model is both scalable and represents a significant revenue potential.

FOCUS 2026

In 2026, AcouSort will continue to develop its cell separation modules in close collaboration with customers within cell therapy. Continued focus will be on technical development to further increase the sample throughput. We've made significant progress regarding the robustness and ease of integration for the high throughput solution that can be used across several different application areas. We will now develop evaluation test kits and focus on internal application development to further strengthen our offering to OEM customers within cell therapy, stem cell isolation, and flow cytometry applications.

1 Cell Therapy Market Size to Hit USD 47.72 Billion by 2034
2 Cell Therapy Market Size to Grow at 22.69% CAGR till 2035
3 Cell Therapy Market Size & Forecast [2035]

Activities 2026

Quarter 1

- Participated in Phacilitate Advanced Therapies Week in San Diego to network with key companies in the cell therapy field working on technologies for cell and gene therapy
- Initiated collaboration with MFX. Collaboration was initiated by a 6-month rental of the AcouWash system to explore cell purification applications for cell therapy production
- Continued work with increasing sample throughput to strengthen AcouSort's offering to customers in cell therapy segment



LAB AUTOMATION

Automated cell separation enables improved end to end workflows for cell analysis



In academic research, pharmaceutical discovery and early development, there is an increasing demand for automated and standardized workflows for analysis and quality control of cell-containing samples. As analytical methods advance, the quality and purity of the input sample is critical to achieve reliable and reproducible results. AcouSort's technology addresses this need by enabling gentle, label-free and continuous cell separation, delivering highly pure cell populations that are directly compatible with automated analytical instruments.

The lab automation market is shifting from a strong focus on automated liquid handling toward automated end-to-end sample workflows, including preparation and purification of cell-containing samples prior to analysis and QC. Growth is driven by higher throughput demands, increasing analytical sensitivity, and the need for standardized, reproducible results with minimal operator dependence. Despite this shift, centrifugation and manual handling remain key bottlenecks to full automation.

MARKET

The global lab automation market is estimated at USD ~8–9 billion, growing at a mid-single to high-single digit CAGR[1]. Growth is driven by increasing sample volumes, labor shortages, and demand for standardized and reproducible workflows in life science research, diagnostics, and biopharma.

Within lab automation, automated handling of cells represents a fast-growing sub-segment, supported by the expansion of cell-based assays, cell and gene therapies, and biologics manufacturing. Automation of cell washing, separation, and culture is increasingly critical to improve reproducibility, scalability, and process robustness compared with manual, pipette-based methods.

OFFERING

By integrating AcouSort's OEM modules or research systems upstream of analysis or QC, laboratories can eliminate centrifugation and manual handling, enabling automated and scalable workflows. This reduces variability, increases throughput, and supports seamless integration into modern lab automation environments.

The value of automation is particularly high in applications reliant on consistent, high-quality input material, such as flow-cytometry analysis, imaging systems, and emerging cell-based assays. By delivering pure, well-defined cell populations, AcouSort helps customers maximize instrument performance, improve data quality, and increase the return on investment in advanced analytical infrastructure.

FOCUS 2026

Going forward, AcouSort will continue to prioritize technology development that supports automation, scalability and integration, strengthening the company's role as a technology provider enabling next-generation workflows for cell analysis and quality control in academic research and pharmaceutical discovery environments.

Activities 2026

Quarter 1

- Participation in SLAS conference to engage with potential customers designing and developing new solutions for automated laboratory workflows.
- Internal activities to develop concept designs for integration of AcouSort separation module to lab automation workflows.
- Installation of AcouWash system at University of Wisconsin to use in project related to improved workflow for cell handling in radiolabelling assays.

1 Lab Automation Market Size & Share | Industry Report, 2033

Active industry collaborations

Collaborations with Life Science companies developing diagnostic systems, cell therapy production equipment and lab automation products represent a cornerstone of AcouSort's strategic transition from research-oriented activities towards OEM (Original Equipment Manufacturer) integration. These collaborations support the Company's long-term objective of embedding its proprietary acoustophoretic technology as integrated modules within third-party medical and laboratory equipment.

Engagements typically commence with the leasing of AcouSort's benchtop systems, the sale of evaluation kits or the execution of limited-scope feasibility studies. Where a strong technological and commercial fit is established, such initial activities may progress into long-term strategic partnerships and formal product development programmes.

The timing of early collaboration phases is inherently difficult to predict, as progress depends on customer priorities, application requirements and internal development resources. Once a collaboration enters formal product development, timelines become more predictable, although they vary by segment. For diagnostic devices, development cycles are typically in the range of approximately three to five years. For cell therapy-related systems, time to market is generally estimated at one to three years, while lab automation products are often characterized by shorter development cycles of approximately one to two years.

Partner	Description	Concept study	Feasibility testing	Early Product development	Formal product development	Validation / beta testing	Product launch
DX1	*Werfen* (Instrumentation Laboratory) License agreement. Press released on June 8, 2018.						2024
CT1	Global life science company active in the cell therapy field. Press released on Nov 14, 2022.						
LA1	Leading life science company developing flow cytometers Press released on May 15, 2023. (Previously FC1)						
LA2	*GenSensor.* Press released on April 29, 2024. (Previously QC1)						
LA3	US based company evaluating sample preparation and cell wash for cytometry-like applications. Press released on April 26, 2024. (Previously FC2)						
CT3	US based cell therapy company. Press released on July 29, 2024.						
LA4	Leading global pharma company evaluating AcouWash for quality control in an R&D setting. Press released on October 23, 2024. (Previously QC2)						
DX2	*Moeller Medical.* Develops diagnostic device containing AcouSort technology. Press released on May 21, 2025.						
LA5	Leading flow cytometry instrument manufacturer. Press released on August 5, 2024. (Previously FC3)						
DX3	UK based company focused on improving sepsis treatment. Press released on March 19, 2025.						
CT4	*Bio Recell.* Press released on March 3, 2025.						
DX4	*SeeQ Diagnostics.* Press released on November 19, 2025.						
CT5	*MFX.* Press released on December 19, 2025.						
LA6	Large international manufacturing company. Press released on January 23, 2026.						

New collaboration, active | Active | Progress in the quarter | Pending | On hold | Discontinued | DX = Diagnostics | CT = Cell Therapy | LA = Lab Automation

AcouSort's research collaborations

To stay at the forefront, AcouSort is continuously developing the acoustofluidic technology further together with universities and commercial partners.

AcouSort was originally spun out from Lund University, Department of Biomedical Engineering (BME) based on research led by Professor Thomas Laurell. Today, more than 20 scientists at BME are active within acoustofluidics representing the largest concentration of acoustofluidics research in the world.

AcouSort has very close collaborations with several of the Primary Investigators at BME and also IP agreements in place securing access to relevant innovations developed.

Over the past years, AcouSort has in addition collaborated with a number of international industrial and academic groups in order to further support our ambition to maintain our leadership as the most advanced commercial and technical player within acoustofluidics.

These collaborations are summarized in the table below, and they address topics ranging from advanced bead-mediated acoustofluidics separation of stem cells over automated exosome isolation to targeting of next generation devices replacing current glass-based devices with plastic.

Project	Sponsor	Goal	Partners	Duration	Status	AcouSort grant	Total project grant
AcouSome	European Innovation Council	Development of a miniaturized microfluidic module for exosome isolation directly from blood using ultrasound generated by thin films, to be used in research and diagnostics.	Lund University, DTU, DayOne	2023-2025	Completed January 2026	EUR 1,100,000	EUR 2,500,000
IndiCell	Vinnova	Development of a world leading innovation milieu for individualized induced pluripotent stem cell derived therapies, to lower the risks and overcome hurdles for the translation from basic science to innovations and further to clinical applications.	Lund University, Karolinska Institute, KTH, Lab-On-A-Bead AB, Skåne University Hospital, BioLamina AB, Karolinska University Hospital	2021-2026	Ongoing	EUR 110,000	EUR 3,520,000*
Blue4Therapy	Eureka, Vinnova, Innovation Fund Denmark	Development of a platform for specific stem cell isolation from autologous adipose tissue for effective regenerative therapy, together with universities and commercial partners.	Blue Cell Therapeutics, University of Southern Denmark, Novozymes A/S	2020-2023	Completed April 2023	EUR 300,000	EUR 800,000
AcouPlast	Eureka, Vinnova, Innovation Fund Denmark	Development of polymer chips to make acoustic separation even more cost efficient and easy to integrate into diagnostic and analytical systems.	DTU, Ortofon A/S, Lund University	2019-2023	Completed Mar 2023	EUR 400,000	EUR 1,000,000
BioWings	EU Horizon 2020	Development of thin films generating the ultrasound used for cell processing to make acoustofluidic chips more efficient and easier to manufacture.	Weizmann Institute of Science, EPFL, PIEMACS, DTU, Lund Univeristy	2018-2022	Completed Nov 2022	EUR 180,000	EUR 3,000,000

*Currency conversion from SEK, i.e. the total project grant in EUR is approximate.

AcouSort's products

OEM COMPONENTS

AcouSort's core strategy is to develop and commercialise Original Equipment Manufacturer (OEM) components for automated sample preparation and processing. These solutions enable the integration of AcouSort's acoustophoretic technology into analytical, diagnostic and therapeutic systems, supporting automated and standardised workflows. The primary customers for OEM components are instrument manufacturers within the life science industry.

The Company aims to expand its OEM portfolio to address a broad range of applications within clinical analysis and biological sample handling. The acoustic separation components are expected to play an important role in the development of next-generation scientific and diagnostic devices, where rapid and automated access to clean cell and blood fractions is required. Similar needs are also seen in therapeutic sample processing systems, including applications related to cancer and stem cell therapies.

Evaluation Kits

To support customer evaluation and integration activities, AcouSort offers evaluation kits to partners interested in exploring the capabilities of the company's acoustofluidic technology and assessing its suitability for integration into their own systems. The kits provide hands-on access to AcouSort's core OEM modules, including the Separation Modules, Trapping Module and AcouPlasmaOptical Module, enabling customers to evaluate performance in relevant application environments.

The evaluation kits are designed to support early-stage development activities, allowing partners to prototype automated sample preparation workflows and assess compatibility with existing analytical, diagnostic or processing platforms. By lowering the threshold for technical evaluation, the kits facilitate structured collaboration and serve as an important step in progressing discussions towards formal OEM development projects.

AcouPlasmaOptical

Integrated separation of biofluids. AcouPlasmaOptical is an OEM component designed for integration into diagnostic and analytical instruments as a semi-consumable. It enables automated and rapid analysis of particle-free media in point-of-care diagnostic devices and monitoring systems. The technology uses gentle acoustic forces in combination with microfluidics to create a particle-free window for optical access in samples without the need for prior centrifugation. Centrifugation often requires manual intervention that may have negative effects on sample quality, making AcouPlasmaOptical a competitive alternative.

Custom made solutions for interfacing of sample flow and electronic connection are available. Design, development and manufacturing of AcouPlasmaOptical is ISO13485 certified.

RESEARCH AND INNOVATION SYSTEMS

AcouSort offers two benchtop research systems that provide customers with hands-on access to the Company's core acoustofluidic techniques, i.e., separation and trapping techniques. Serving as research and innovation platforms, the instruments provide easy access to the technology for instrument manufacturers interested in integrating acoustofluidic OEM components into their systems. With user-friendly hardware and software, the instruments enable automated handling of biological samples, supporting academic researchers and product development teams working with new biomarker identification and diagnostic assay development.

AcouWash

Automated cell separation. AcouWash is a benchtop research instrument for label-free separation of target cells from a variety of biological samples. The system provides automated processing and is designed to perform sensitive separations and handle fragile cells without any impact on viability. The acoustic forces used in the AcouWash provides samples with very high quality and with minimal sample-to-sample variation.

With the AcouWash system, a variety of applications aimed at separation of blood cells can be automated. Common applications comprise gentle and highly efficient cell wash, label-free separation of mononuclear cells and platelets from blood, and rare cell isolation (e.g., bead mediated separations) for research and product development applications.

AcouTrap

Sample enrichment and preparation. AcouTrap is a benchtop research instrument for automated enrichment, washing and labelling of cells and nanoparticles in biological samples. The system enables gentle handling of cells and other biological particles and is primarily used in research and development environments where high recovery and preservation of sample integrity are critical.

AcouTrap supports a range of sample preparation workflows and is used by customers to explore applications and perform feasibility studies and where the system is particularly well suited for research studies with small volume samples for example biobank samples only provided in minute fluid volumes.

Income statement – Group

(SEK thousand)	1/1/2026 3/31/2026	1/1/2025 3/31/2025	1/1/2025 12/31/2025
Operating income			
Net sales	2,147	1,595	6,853
Other income	102	1,034	3,579
Total income	**2,249**	**2,629**	**10,432**
Operating expenses			
Raw materials	-88	-51	-111
Other external expenses	-1,835	-1,681	-6,928
Personnel costs	-3,351	-4,181	-14,141
Depreciations	-23	-49	-175
Total expenses	**-5,297**	**-5,962**	**-21,355**
OPERATING RESULT	**-3,048**	**-3,333**	**-10,923**
Result from financial items			
Financial income	679	18	114
Financial expenses	-8	-707	-1,336
Total financial items	**679**	**-689**	**-1,223**
Result after financial items	**-2,369**	**-4,022**	**-12,146**
Result before taxes	**-2,369**	**-4,022**	**-12,146**
Tax on this year's result	0	0	-8
Result for the period	**-2,369**	**-4,022**	**-12,153**
Result per share, SEK - before dilution	-0.11	-0.27	-0.64
Result per share, SEK - after dilution	-0.10	-0.26	-0.60

Apparently incorrect sums are explained by rounding in the rows leading to the sum.

Operating results

For the first quarter of the year, the parent company reported net sales of TSEK 2,144 (1,569), which consisted of product sales of TSEK 713 (280) and royalty income of TSEK 1,431 (1,289). Other operating income consists of research grants amounting to TSEK 21 (1,034) and rental income of TSEK 81 (0). The reduction in the research grant is due to the project being completed in 2025.

Raw materials for the period amounted to TSEK -88 (-51). Other external expenses for the period amounted to TSEK -1,763 (-1,548). Personnel costs for the period amounted to TSEK -3,351 (-4,181). Depreciation for the period amounted to TSEK -23 (-49).

The first quarter's operating result for the parent company totalled TSEK -2,980 (-3,226).

Total income, SEK thousand



AcouSort has been successful in applying for public R&D grants within Sweden and the EU. Since 2021, AcouSort has been awarded SEK 20.5 million in research and development grants.

Balance sheet – Group

ASSETS (SEK thousand)	3/31/2026	12/31/2025
Fixed assets		
Intangible assets		
Concessions, patents, licenses, trademarks, and similar rights	4,953	4,845
Total intagible assets	**4,953**	**4,845**
Tangible assets		
Equipment, tools, and installations	-	-
Total tangible assets	**-**	**-**
Financial assets		
Other long-term receivables	12	12
Total financial assets	**12**	**12**
Total fixed assets	**4,965**	**4,857**
Current assets		
Inventories	2,521	2,565
Account receivable	303	111
Other receivables	2,252	323
Prepaid expenses and accrued income	1,911	3,745
Cash and cash equivalents	14,572	6,291
Total current assets	**21,559**	**13,036**
TOTAL ASSETS	**26,525**	**17,893**

EQUITY AND LIABILITIES (SEK thousand)	3/31/2026	12/31/2025
Equity		
Restricted equity		
Share capital	2,116	2,116
	2,116	**2,116**
Non-restricted equity		
Other contributed capital	117,470	117,470
Reserves	-3	72
Retained earnings	-103,478	-91,206
Profit/loss for the period	-2,369	-12,153
	11,621	**14,183**
Total equity	**13,737**	**16,301**
Current liabilities		
Account payables	612	444
Tax liabilities	0	67
Other liabilities	272	250
Accrued expenses and deferred income	11,904	831
Total current liabilities	**12,788**	**1,592**
TOTAL EQUITY AND LIABILITIES	**26,525**	**17,893**

Financial Position

On March 31, 2026, AcouSort Group's equity ratio was 52% (41). Equity amounted to TSEK 13,737 (4,868). Cash and cash equivalents amounted to TSEK 14,572 (3,448). Under accrued expenses and prepaid income, 11,904 (831) is reported the advance payment of royalties received during the quarter of 1.3 million USD. Total assets for the Group amounted to TSEK 26,525 (11,770).

Apparently incorrect sums are explained by rounding in the rows leading to the sum.

Statement of changes in equity – Group

(SEK thousand)	Share capital	Other contributed capital	Reserves	Retained earnings	Loss for the period	Total
Opening balance January 1, 2025	**1,493**	**99,116**	**-45**	**-77,024**	**-15,078**	**8,463**
Prior year´s result	0	0	0	-15,078	15,078	0
Conversion difference	0	0	117	896	0	1,013
Warrants, Serie 2025/2028	0	166	0	0	0	166
Rights issue	623	24,296	0	0	0	24,919
Costs, rights issue	0	-6,107	0	0	0	-6,107
Loss for the period	0	0	0	0	-12,152	-12,152
Equity December 31, 2025	**2,116**	**117,470**	**72**	**-91,206**	**-12,152**	**16,301**
Opening balance January 1, 2026	**2,116**	**117,470**	**72**	**-91,206**	**-12,152**	**16,301**
Prior year´s result	0	0	0	-12,152	12,152	0
Conversion difference	0	0	-75	-120	0	-195
Loss for the period	0	0	0	0	-2,369	-2,369
Equity March 31, 2026	**2,116**	**117,470**	**-3**	**-103,478**	**-2,369**	**13,737**

Apparently incorrect sums are explained by rounding in the rows leading to the sum.

Cash flow statement – Group

(SEK thousand)	1/1/2026 3/31/2026	1/1/2025 3/31/2025	1/1/2025 12/31/2025
Operating activities			
Operating result	-3,048	-3,333	-10,923
Depreciations	23	49	175
Financial income / expense	679	-689	-1,222
Paid taxes	0	0	-8
Cash flow from operating activities before changes in working capital	**-2,346**	**-3,973**	**-11,978**
Change in working capital			
Increase/decrease inventories	44	26	-40
Increase/decrease in receivables	-287	517	-2,493
Increase/decrease in current liabilities	11,196	3,040	-2,269
Changes in working capital	**10,953**	**3,583**	**-4,802**
Cash flow from operating activities	**8,607**	**-390**	**-16,780**
Investing activities			
Increase/decrease of intangible assets	-131	-105	-488
Increase/decrease of financial assets	0	-54	0
Cash flow from investing activities	**-131**	**-159**	**-488**
Financing activities			
Rights issue	0	0	24,919
Costs, rights issue	0	-85	0
Warrants	0	0	-6,107
Increase/decrease of long-term liabilities	0	0	166
Cash flow from financing activities	**0**	**-85**	**18,977**
Change in cash and cash equivalents	8,476	-633	1,709
Cash and cash equivalents at the beginning of the period	6,291	3,568	3,568
Conversion difference and other adjustments	-195	512	1,014
Cash and cash equivalents at the end of the period	**14,572**	**3,448**	**6,291**

Apparently incorrect sums are explained by rounding in the rows leading to the sum.

Cash flow and investments

AcouSort Group's cash flow for the first quarter of the year was TSEK 8,476 (-633). The increase in short-term liabilities (11,196) consists primarily of the royalty received in advance of USD 1.3 million. Investments amounted to TSEK -131 (-159), of which TSEK -131 (-105) pertained to intangible assets and TSEK 0 (-54) to financial assets.

Cash and cash equivalents last five quarters, SEK thousand



At the end of the first quarter, the Group had cash and cash equivalents amounting to TSEK 14,572. This cash position allow AcouSort to continue its planned activities for the coming twelve-month period.

Income statement – Parent company

(SEK thousand)	1/1/2026 3/31/2026	1/1/2025 3/31/2025	1/1/2025 12/31/2025
Operating income			
Net sales	2,144	1,569	6,799
Other income	102	1,034	3,579
Total income	**2,246**	**2,603**	**10,378**
Operating expenses			
Raw materials	-88	-51	-111
Other external expenses	-1,763	-1,548	-6,680
Personnel costs	-3,351	-4,181	-14,141
Depreciations	-23	-49	-175
Total expenses	**-5,226**	**-5,829**	**-21,107**
OPERATING RESULT	**-2,980**	**-3,226**	**-10,730**
Result from financial items			
Loss from receivables in group companies*	0	0	-2,000
Financial income	679	18	734
Financial expenses	-0	-707	-1,336
Total financial items	679	-689	-2,603
Result after financial items	**-2,301**	**-3,915**	**-13,332**
Result before taxes	**-2,301**	**-3,915**	**-13,332**
Tax on this year's result	0	0	0
Result for the period	**-2,301**	**-3,915**	**-13,332**

*Write-down has been made of the receivables towards AcouSort INC, corresponding to SEK 2.0 million.

Operating results

For the first quarter of the year, the parent company reported net sales of TSEK 2,144 (1,569), which consisted of product sales of TSEK 713 (280) and royalty income of TSEK 1,431 (1,289). Other operating income consists of research grants amounting to TSEK 21 (1,034) and rental income of TSEK 81 (0). The reduction in the research grant is due to the project being completed in 2025.

Raw materials for the period amounted to TSEK -88 (-51). Other external expenses for the period amounted to TSEK -1,763 (-1,548). Personnel costs for the period amounted to TSEK -3,351 (-4,181). Depreciation for the period amounted to TSEK -23 (-49).

The first quarter's operating result for the parent company totalled TSEK -2,980 (-3,226).

Apparently incorrect sums are explained by rounding in the rows leading to the sum.

Balance sheet – Parent company

ASSETS (SEK thousand)	3/31/2026	12/31/2025
Fixed assets		
Intangible assets		
Concessions, patents, licenses, trademarks, and similar rights	4,953	4,845
Total intagible assets	**4,953**	**4,845**
Tangible assets		
Equipment, tools, and installations	0	0
Total tangible assets	**0**	**0**
Financial assets		
Shares in group companies	9	8.857
Receivables from group companies*	2,105	1,830
Other long-term receivables	12	12
Total financial assets	2,126	1,851
Total fixed assets	**7,079**	**6,697**
Current assets		
Inventories	2,521	2,565
Account receivables	303	111
Other receivables	2,252	323
Prepaid expenses and accrued income	1,911	3,731
Cash and cash equivalents	14,026	6,045
Total current assets	**21,013**	**12,776**
TOTAL ASSETS	**28,091**	**19,473**

EQUITY AND LIABILITIES (SEK thousand)	3/31/2026	12/31/2025
Equity		
Restricted equity		
Share capital	2,116	2,116
Development expense fund	4,953	4,845
	7,069	**6,962**
Non-restricted equity		
Share premium	117,470	117,470
Retained earnings	-106,659	-93,219
Profit/loss for the period	-2,301	-13,332
	8,510	**10,919**
Total equity	**15,579**	**17,881**
Current liabilities		
Account payables	612	444
Tax liabilities	0	67
Other liabilities	272	250
Accrued expenses and deferred income	11,628	831
Total current liabilities	**12,512**	**1,592**
TOTAL EQUITY AND LIABILITIES	**28,091**	**19,473**

*Write-down has been made of the receivables towards AcouSort INC, corresponding to SEK 2.0 million.

Financial Position

On March 31, 2026, the parent company's equity ratio was 55% (54). Equity amounted to TSEK 15,579 (8,235). Cash and cash equivalents amounted to TSEK 14,026 (3,206). Under accrued expenses and prepaid income, 11,628 (831) is reported the advance payment of royalties received during the quarter of 1.3 million USD. Total assets amounted to TSEK 28,091 (15,137).

Apparently incorrect sums are explained by rounding in the rows leading to the sum.

Statement of changes in equity – Parent company

(SEK thousand)	Share capital	Development expense fund	Share premium	Retained earnings	Loss for the period	Total
Opening balance January 1, 2025	**1,493**	**4,448**	**99,116**	**-76,974**	**-15,848**	**12,236**
Prior year´s result	0	0	0	-15,848	15,848	0
Development expense fund	0	397	0	-397	0	0
Warrants, Serie 2025/2028	0	0	166	0	0	166
Rights issue	623	0	24,296	0	0	24,919
Costs, rights issue	0	0	-6,107	0	0	-6,107
Loss for the period	0	0	0	0	-13,332	-13,332
Equity December 31, 2025	**2,116**	**4,845**	**117,470**	**-93,219**	**-13,332**	**17,881**
Opening balance January 1, 2026	**2,116**	**4,845**	**117,470**	**-93,219**	**-13,332**	**17,881**
Prior year´s result	0	0	0	-13,332	13,332	0
Development expense fund	0	108	0	-108	0	0
Loss for the period	0	0	0	0	-2,301	-2,301
Equity March 31, 2026	**2,116**	**4,953**	**117,470**	**-106,659**	**-2,301**	**15,579**

Apparently incorrect sums are explained by rounding in the rows leading to the sum.

Cash flow statement – Parent company

(SEK thousand)	1/1/2026 3/31/2026	1/1/2025 3/31/2025	1/1/2025 12/31/2025
Operating activities			
Operating result	-2,980	-3,226	-10,730
Depreciations	23	49	175
Financial net	679	-689	-2,603
Cash flow from operating activities before changes in working capital	**-2,279**	**-3,866**	**-13,157**
Change in working capital			
Increase/decrease inventories	44	26	-40
Increase/decrease in receivables	-301	453	-2,611
Increase/decrease in current liabilities	10,920	3,041	-2,269
Changes in working capital	**10,663**	**3,520**	**-4,920**
Cash flow from operating activities	**8,385**	**-346**	**-18,077**
Investing activities			
Increase/decrease of intangible assets	-130	-105	-488
Increase/decrease of financial assets	-275	700	2,591
Cash flow from investing activities	**-405**	**595**	**2,103**
Financing activities			
Rights issue	0	0	24,919
Costs, rights issue	0	-85	0
Warrants	0	0	-6,107
Increase/decrease of long-term liabilities	0	0	166
Cash flow from financing activities	**0**	**-85**	**18,977**
Change in cash and cash equivalents	7,979	164	3,003
Cash and cash equivalents at the beginning of the period	6,045	3,042	3,042
Cash and cash equivalents at the end of the period	**14,026**	**3,206**	**6,045**

Apparently incorrect sums are explained by rounding in the rows leading to the sum.

Cash flow and investments

The parent company's cash flow for the first quarter was TSEK 7 980 (164). The increase in short-term liabilities (10,920) consists primarily of the royalty received in advance of USD 1.3 million. Investments amounted to TSEK -512 (595), of which TSEK -130 (-105) pertained to intangible assets and TSEK -382 (700) to financial assets.

Other information

THE SHARE

AcouSort's share was listed on Spotlight Stock Market January 9th, 2017. In December 2020 the share changed list to Nasdaq First North Growth Market, with December 14th as the first trading day. The ticker symbol of the share is "ACOU", and the ISIN-code is SE0009189608. First North Growth Market is an alternative marketplace run by NASDAQ OMX GROUP. Companies traded on First North Growth Market do not have to be compliant to the same rules as companies traded on a regulated market. Instead, the companies follow under less strict rules applied for growth companies. The risk of investing in a company traded on First North Growth Market may thus be greater than investing in a company traded on a regulated market. All companies with shares traded on First North Growth Market have a Certified Adviser that supervises the compliance of the rules. The stock exchange examines applications to be listed on the exchange. AcouSort's Certified Adviser on Nasdaq First North Growth Market is Tapper Partners AB (publ), +46 (0)70 44 010 98. As of March 31, 2026, the number of shares in AcouSort AB was 21,163,902 (14,934,140). The Company has one class of shares. Each share carries one (1) vote per share and carries equal rights to share in the Company's assets and earnings.

THE SUBSIDIARY ACOUSORT INC

AcouSort AB has a wholly owned subsidiary in the USA, AcouSort Inc. The Company's task is to carry out marketing and sales on the North American market.

BUSINESS-RELATED RISKS AND UNCERTAINTIES

In summary, the risks and uncertainties that AcouSort's operations are exposed to are related to, among other things, competition, technology development, market conditions, capital needs, currencies and interest rates. No significant changes in risk or uncertainty factors occurred during the current period. For more detailed reporting of risks and uncertainties, please refer to the Annual Report.

The group makes continuous simulations regarding expected liquidity development for the coming twelve-month period. These simulations are based on the current order backlog, ongoing EU-funded R&D projects, planned investments as well as operational costs. The Group's simulations show that the Group has sufficient liquidity for the coming twelve-month period.

In a scenario where the Group would not succeed in achieving the budgeted sales revenues, there is a potential risk the Group may experience liquidity problems. This means that liquidity development constitutes an uncertainty factor regarding the Group's continued operations. It is the Group's current assessment that such a situation can be handled without a new issue being carried out.

UPCOMING FINANCIAL REPORTS

- Q2 2026: August 26, 2026
- Q3 2026: November 25, 2026
- Q4 2026: February 24, 2027

REVIEW BY AUDITORS

The interim report has not been reviewed by the Company's auditor.

PRINCIPLES FOR THE INTERIM REPORT'S ESTABLISHMENT

The interim report has been prepared in accordance with the Swedish Accounting Standards Board's General Council 2012:1 Annual Report and Consolidated Accounts (K3) and the Annual Accounts Act.

	Jan- Mar 2026	Jan - Mar 2025	Jan- Dec 2025
Number of shares before dilution	21,163,902	14,934,140	21,163,902
Number of shares after dilution	22,700,900	15,486,138	22,700,900
Result per share before and after dilution	-0.11	-0.26	-0.64
Average number of shares before dilution	21,163,902	14,934,140	18,859,743
Average number och shares after dilution	22,700,900	15,486,138	20,396,741

Declaration by the Board of Directors and the CEO

Stefan Blomsterberg

Thomas Laurell

Stefan Scheding

Katherine Flagg

Per Sundkvist

Torsten Freltoft

The Board of Directors and the Chief Executive Officer certify that the interim report provides a true and fair view of the Company's business, financial position, performance and describes material risks and uncertainties, to which the Company is exposed.

The report has not been reviewed by the Company's auditors.

Lund, May 27, 2026

Stefan Blomsterberg
Chairman

Thomas Laurell
Board member

Stefan Scheding
Board member

Katherine Flagg
Board member

Per Sundkvist
Board member

Torsten Freltoft
CEO

For further information, contact:

Torsten Freltoft, CEO
Telephone: +45 20 450 854
E-mail: torsten.freltoft@acousort.com
Website: www.acousort.com
Address: Medicon Village, SE-223 81 LUND, Sweden



AcouSort

revolutionizing sample processing